A randomized controlled trial published in the New England Journal of Medicine has revealed that adding mycophenolate mofetil (MMF) to a glucocorticoid as first-line therapy for immune thrombocytopenia (ITP) led to better responses and a decrease in the risk of relapse or refractory disease.

Patients who were administered MMF/glucocorticoid combination reported half the number of treatment failures in comparison with patients who were given glucocorticoids only (22% vs 44%, respectively; HR 0.41, 95% CI 0.21-0.80). Furthermore, patients receiving the combination therapy achieved a greater response - 91.5% had platelet levels above 100 × 10⁹/L compared to 63.9% of patients treated with the glucocorticoid alone… (Medpage Today)